LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Aktien・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

31.17 0.06

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

31.16

Max

31.17

Schlüsselkennzahlen
By Trading Economics
Einkommen	11M 64M
Verkäufe	-3.2M 149M
KGV Branchendurchschnitt	18.542 51.415
EPS	0.68
Gewinnspanne	42.663
Angestellte	182
EBITDA	-7.8M 73M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+6.16% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	5. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	271M 3.8B
Vorheriger Eröffnungskurs	31.11
Vorheriger Schlusskurs	31.17

Nachrichtenstimmung

By Acuity

50%

137 / 345 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

N/A / 24.28 Unterstützung & Widerstand

Catalyst Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Mai 2026, 22:47 UTC

Heiße Aktien

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15. Mai 2026, 22:16 UTC

Akquisitionen, Fusionen, Übernahmen

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15. Mai 2026, 22:00 UTC

Wichtige Markttreiber

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15. Mai 2026, 18:09 UTC

Wichtige Markttreiber

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15. Mai 2026, 16:02 UTC

Ergebnisse

Wichtige Markttreiber

Forward Industries Shares Fall on New Debt as Solana Value Drops

15. Mai 2026, 14:55 UTC

Wichtige Markttreiber

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

16. Mai 2026, 16:27 UTC

Akquisitionen, Fusionen, Übernahmen

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16. Mai 2026, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. Mai 2026, 22:17 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15. Mai 2026, 21:59 UTC

Akquisitionen, Fusionen, Übernahmen

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15. Mai 2026, 21:50 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15. Mai 2026, 21:30 UTC

Akquisitionen, Fusionen, Übernahmen

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15. Mai 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15. Mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. Mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. Mai 2026, 20:19 UTC

Heiße Aktien

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15. Mai 2026, 19:41 UTC

Akquisitionen, Fusionen, Übernahmen

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15. Mai 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15. Mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15. Mai 2026, 18:35 UTC

Ergebnisse

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15. Mai 2026, 17:28 UTC

Market Talk

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15. Mai 2026, 16:50 UTC

Akquisitionen, Fusionen, Übernahmen

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15. Mai 2026, 16:24 UTC

Akquisitionen, Fusionen, Übernahmen

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15. Mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

15. Mai 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. Mai 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. Mai 2026, 15:55 UTC

Market Talk

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15. Mai 2026, 15:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. Mai 2026, 15:20 UTC

Market Talk

Silver Plunges on Inflation Worries -- Market Talk

15. Mai 2026, 15:20 UTC

Ergebnisse

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

Peer-Vergleich

Kursveränderung

Catalyst Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

6.16% Vorteil

12-Monats-Prognose

Durchschnitt 33.1 USD 6.16%

Hoch 35 USD

Tief 31.5 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Catalyst Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

7 ratings

Buy

Halten

Sell

Basierend auf 7 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Catalyst Pharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

N/A / 24.28Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Stimmung

By Acuity

137 / 345 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.